Literature DB >> 21750314

Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation.

Rieneke van de Ven1, Mari F C M van den Hout, Jelle J Lindenberg, Berbel J R Sluijter, Paul A M van Leeuwen, Sinéad M Lougheed, Sybren Meijer, M Petrousjka van den Tol, Rik J Scheper, Tanja D de Gruijl.   

Abstract

To increase (tumor) vaccine efficacy, there is an urgent need for phenotypic and functional characterization of human dendritic cell (DC) subsets residing in lymphoid tissues. In this study we identified and functionally tested 4 human conventional DC (cDC) subsets within skin-draining sentinel lymph nodes (SLNs) from early-stage melanoma patients. These SLNs were all tumor negative and were removed on average 44 days after excision of the primary melanoma. As such, they were considered representative of steady-state conditions. On comparison with skin-migrated cDC, 2 CD1a(+) subsets were identified as most likely skin-derived CD11c(int) Langerhans cells (LC) with intracellular langerin and E-cadherin expression or as CD11c(hi) dermal DCs with variable expression of langerin. Two other CD1a(-) LN-residing cDC subsets were characterized as CD14(-)BDCA3(hi)CD103(-) and CD14(+)BDCA3(lo)CD103(+), respectively. Whereas the CD1a(+) skin-derived subsets displayed greater levels of phenotypic maturation, they were associated with lower levels of inflammatory cytokine release and were inferior in terms of allogeneic T-cell priming and IFNγ induction. Thus, despite their higher maturation state, skin-derived cDCs (and LCs in particular) proved inferior T-cell activators compared with the CD1a(-) cDC subsets residing in melanoma-draining LNs. These observations should be considered in the design of DC-targeting immunotherapies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21750314     DOI: 10.1182/blood-2011-03-344838

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  Langerhans-Cell Histiocytosis.

Authors:  Carl E Allen; Miriam Merad; Kenneth L McClain
Journal:  N Engl J Med       Date:  2018-08-30       Impact factor: 91.245

Review 2.  Experimental models to investigate the function of dendritic cell subsets: challenges and implications.

Authors:  D G Hancock; T V Guy; E Shklovskaya; B Fazekas de St Groth
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

Review 3.  Increasing the efficacy of tumor cell vaccines by enhancing cross priming.

Authors:  Brian M Andersen; John R Ohlfest
Journal:  Cancer Lett       Date:  2012-07-16       Impact factor: 8.679

4.  Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis.

Authors:  Kazuhiro Okumura; Megumi Saito; Yasuhiro Yoshizawa; Yuki Ito; Eriko Isogai; Kimi Araki; Yuichi Wakabayashi
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

5.  Retinoic acid imprints a mucosal-like phenotype on dendritic cells with an increased ability to fuel HIV-1 infection.

Authors:  Natalia Guerra-Pérez; Ines Frank; Filippo Veglia; Meropi Aravantinou; Diana Goode; James L Blanchard; Agegnehu Gettie; Melissa Robbiani; Elena Martinelli
Journal:  J Immunol       Date:  2015-01-26       Impact factor: 5.422

6.  In situ Delivery of Tumor Antigen- and Adjuvant-Loaded Liposomes Boosts Antigen-Specific T-Cell Responses by Human Dermal Dendritic Cells.

Authors:  Martine A Boks; Sven C M Bruijns; Martino Ambrosini; Hakan Kalay; Louis van Bloois; Gert Storm; Tanja de Gruijl; Yvette van Kooyk
Journal:  J Invest Dermatol       Date:  2015-06-17       Impact factor: 8.551

7.  In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity.

Authors:  Jurjen M Ruben; Hetty J Bontkes; Theresia M Westers; Erik Hooijberg; Gert J Ossenkoppele; Arjan A van de Loosdrecht; Tanja D de Gruijl
Journal:  Oncoimmunology       Date:  2014-07-03       Impact factor: 8.110

Review 8.  The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?

Authors:  Muki S Shey; Nigel J Garrett; Lyle R McKinnon; Jo-Ann S Passmore
Journal:  Innate Immun       Date:  2013-11-26       Impact factor: 2.680

9.  Langerin-mediated internalization of a modified peptide routes antigens to early endosomes and enhances cross-presentation by human Langerhans cells.

Authors:  Cynthia M Fehres; Sanne Duinkerken; Sven Cm Bruijns; Hakan Kalay; Sandra J van Vliet; Martino Ambrosini; Tanja D de Gruijl; Wendy Wj Unger; Juan J Garcia-Vallejo; Yvette van Kooyk
Journal:  Cell Mol Immunol       Date:  2015-10-12       Impact factor: 11.530

Review 10.  Targeting human dendritic cells in situ to improve vaccines.

Authors:  Kartik Sehgal; Kavita M Dhodapkar; Madhav V Dhodapkar
Journal:  Immunol Lett       Date:  2014-07-27       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.